Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Jang HS, Kang KM, Choi BO, Chai GY, Hong SC, Ha WS, Jirtle RL. Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma. World J Gastroenterol 2008; 14(9): 1394-1398 [PMID: 18322954 DOI: 10.3748/wjg.14.1394]
World J Gastroenterol. Mar 7, 2008; 14(9): 1394-1398 Published online Mar 7, 2008. doi: 10.3748/wjg.14.1394
Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma
Hong Seok Jang, Ki Mun Kang, Byung Ock Choi, Gyu Young Chai, Soon Chan Hong, Woo Song Ha, Randy L Jirtle
Hong Seok Jang, Byung Ock Choi, Department of Radiation Oncology, The Catholic University of Korea, School of Medicine, Seoul, Korea
Ki Mun Kang, Gyu Young Chai, Department of Radiation Oncology, Gyeongsang National University, Postgraduate School of Medicine, Gyeongsang Institute of Health Sciences, Jinju 660-702, Korea
Soon Chan Hong, Woo Song Ha, Department of Surgery, Gyeongsang National University, Postgraduate School of Medicine, Jinju 660-702, Korea
Randy L Jirtle, Department of Radiation Oncology, Duke University Medical Center, Durham, NC, United States
Correspondence to: Ki Mun Kang, MD, PhD, Department of Radiation Oncology, Gyeongsang National University, School of Medicine, 90 Chilamdong, Jinju 660-702, Korea. jsk92@gnu.ac.kr
Telephone: +82-55-7509202
Fax: +82-55-7509095
Received: October 14, 2007 Revised: November 30, 2007 Published online: March 7, 2008
Abstract
AIM: To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy.
METHODS: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy.
RESULTS: M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P = 0.04) and the disease-free survival rate (17.8% vs 59.3%; P = 0.03).
CONCLUSION: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
